Quigley Pharma filed the patent application based upon observations that subjects participating in a proof of concept study using QR-333 had further improvements over and above the existing protocol. A significant observation regarding the improved color of study patient’s feet led the company to conclude that topical application of the compound may have led to improved peripheral circulation.
A data search evaluating the active ingredients indicated that they could have the potential to impact upon the human circulation system as vasodilators. This important new information provided the rationale for the company to file the separate patent application.
“The possibility of developing a drug that not only relieves the symptoms of diabetic peripheral neuropathy, but also improves circulation, would fulfill a significant therapeutic need,” stated Dr Richard Rosenbloom, COO of Quigley Pharma.
QR-333 is designed and formulated to decrease oxidative stress that can contribute to the relief of symptoms associated with diabetic peripheral neuropathy. The first of two human clinical trials on QR-333 began in May after a FDA review of the investigational new drug application for the compound.